Glossary

Medicare drug price negotiation

A program in which Medicare negotiates prices for selected high-spending drugs with their makers, with agreed prices applying to Medicare Part B and Part D.

Also called: Medicare negotiation, maximum fair price, IRA drug price negotiation, negotiated drug prices

Under the Inflation Reduction Act of 2022, CMS selects certain high-spending drugs with no generic or biosimilar competitor and negotiates a "maximum fair price" with each maker. The agreed price applies to Medicare, meaning Medicare Part D and Part B, not to employer or marketplace plans, and not to the cash price at the pharmacy.

The program runs in cycles. The first 10 drugs, including Eliquis, Enbrel, Jardiance and Xarelto, got negotiated prices on January 1, 2026. A second group of 15, including Ozempic, Wegovy and Rybelsus, takes effect January 1, 2027. A third group of 15 plus one drug selected for renegotiation takes effect January 1, 2028. The CMS Medicare drug price negotiation page lists the current drugs and prices.

Your own cost is based on the lower price. As a labeled hypothetical, with 25% coinsurance a drug with a $500 price costs you $125, and at a negotiated $300 it costs $75. The Part D out-of-pocket cap ($2,100 in 2026, $2,400 in 2027) still limits yearly spending. The second group matters for weight-loss and diabetes drugs; see GLP-1 drug coverage for how those are covered.

The common mistake is expecting a drug's price to fall for everyone. Manufacturers have challenged the program in court, and details change, so check Medicare.gov and your plan's formulary.

Last reviewed November 16, 2026

In the index now

Related terms

Related guides

Related blog